416 related articles for article (PubMed ID: 27764780)
1. The concept of immune surveillance against tumors. The first theories.
Ribatti D
Oncotarget; 2017 Jan; 8(4):7175-7180. PubMed ID: 27764780
[TBL] [Abstract][Full Text] [Related]
2. Challenges and prospects of immunotherapy as cancer treatment.
Rescigno M; Avogadri F; Curigliano G
Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunoediting: from immunosurveillance to tumor escape.
Dunn GP; Bruce AT; Ikeda H; Old LJ; Schreiber RD
Nat Immunol; 2002 Nov; 3(11):991-8. PubMed ID: 12407406
[TBL] [Abstract][Full Text] [Related]
4. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
5. [Immune system and tumors].
Terme M; Tanchot C
Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive cells in tumor immune escape and metastasis.
Liu Y; Cao X
J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
[TBL] [Abstract][Full Text] [Related]
7. The three Es of cancer immunoediting.
Dunn GP; Old LJ; Schreiber RD
Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Schreiber RD; Old LJ; Smyth MJ
Science; 2011 Mar; 331(6024):1565-70. PubMed ID: 21436444
[TBL] [Abstract][Full Text] [Related]
9. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
10. Strategies of tumor immune evasion.
Seliger B
BioDrugs; 2005; 19(6):347-54. PubMed ID: 16392887
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
12. Reverse immunoediting: When immunity is edited by antigen.
Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
[TBL] [Abstract][Full Text] [Related]
13. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
Salih HR; Nüssler V
Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunoediting from immune surveillance to immune escape.
Kim R; Emi M; Tanabe K
Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
[TBL] [Abstract][Full Text] [Related]
15. The two sides of HER2/neu: immune escape versus surveillance.
Seliger B; Kiessling R
Trends Mol Med; 2013 Nov; 19(11):677-84. PubMed ID: 24035606
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy: the past, the present and the future.
Parish CR
Immunol Cell Biol; 2003 Apr; 81(2):106-13. PubMed ID: 12631233
[TBL] [Abstract][Full Text] [Related]
17. [A retrospective view of tumor immunology].
Dosne Pasqualini C
Medicina (B Aires); 1996; 56 Suppl 1():3-12. PubMed ID: 9224970
[TBL] [Abstract][Full Text] [Related]
18. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Fridman WH
Bull Cancer; 2016 Nov; 103 Suppl 1():S122-S126. PubMed ID: 28057174
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell-mediated immunosurveillance of human cancer.
Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
